Influence of Statin Potency and Liposolubility on Alzheimer's disease patients: a population-based study.

Autores de IIS La Fe

• Maria Del Mar Garcia Zamora

  Autor

• Gemma María García Lluch

  Autor

• 

  María Consuelo Cháfer Pericás

  Autor

Participantes ajenos a IIS La Fe

• Moreno, Lucrecia
• Pardo, Juan

Grupos

• Grupo de Investigación en Enfermedad de Alzheimer (GINEA)

Abstract

Although Alzheimer's disease (AD) cause is still unknown, there are several known risk factors, such as dyslipidemia. Statins are the most prescribed lipid-modifying therapies. Recent research has suggested a relationship between statins and AD, nevertheless, their ability to prevent AD is still unclear. Therefore, this cross-sectional study aimed to examine the relationship between statin use and anti-AD drug prescription. For that purpose, a database containing information on medications prescribed to patients aged 50 years or older (n = 233183) between 2018 and 2020 was used. Defined daily doses (DDDs) were calculated according to the ATC/DDD index 2023. Statistical analyses, with logistic regression and cumulative incidence, were carried out to assess statins and anti-AD drug consumption. As a result, a total of 47852 patients aged more than 70 years who were prescribed at least one antihypertensive, antidiabetic or lipid-modifying agent were included in the study. Of these, 45345 patients were classified within the cardiovascular risk group and 2483 were classified as patients with only hyperlipidemia. Patients using low-potency or hydrophilic statins had lower odds of anti-AD usage when compared to high-potency or lipophilic statins, respectively. Similarly, rosuvastatin and pitavastatin had lower odds of anti-AD medication intake when compared to atorvastatin. Finally, pitavastatin DDDs were prone to lower the odds of anti-AD medication usage when compared to rosuvastatin. In conclusion, a potential association between statins and the intake of AD medication has been observed. Specifically, low-potency (pitavastatin) and hydrophilic (rosuvastatin) statins were associated with less use of anti-AD medication.

Copyright © 2024. Published by Elsevier Ltd.

Keywords

• Alzheimer’s disease; liposolubility; pitavastatin; potency; real-world study; statins